This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dr. Lesley Russell Joins The Endocyte Board Of Directors

WEST LAFAYETTE, Ind., Jan. 8, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced Lesley Russell, M.B.Ch.B., has joined the Endocyte board of directors.

Dr. Russell served as senior vice president and head of research and development for global branded products at Teva Pharmaceuticals until June 2012. Prior to this position she was executive vice president and chief medical officer at Cephalon. Dr. Russell joined Cephalon in 2000 and held various positions of increasing responsibility, including head of clinical research and medical affairs, prior to becoming Cephalon's chief medical officer in September 2006. During her tenure at Cephalon, Dr. Russell filed multiple new drug applications (NDAs) to the FDA and marketing authorization applications (MAAs) to the Committee for Medicinal Products for Human Use (CHMP). Before joining Cephalon, Dr. Russell held positions of increasing responsibility at Amgen U.K., Lilly Industries, U.K., and U.S. Bioscience, now acquired by MedImmune Oncology.

"Dr. Russell's experience in advancing products through late-stage clinical development will be important to Endocyte as we continue to build our portfolio of SMDCs to develop novel cancer and inflammatory drugs in areas of great medical need," commented Ron Ellis, president and CEO of Endocyte. "In addition, Dr. Russell has been successful in navigating the new drug approval process at the FDA, which will be important as our drugs approach the late stages of clinical development. We are pleased to welcome her to our board."

Before joining the pharmaceutical industry, Dr. Russell was trained in hematology and oncology at Royal Infirmary of Edinburgh and at Royal Hospital for Sick Children in Edinburgh, Scotland, and was a research fellow at University of Edinburgh. Dr. Russell received a M.B.Ch.B. degree from the University of Edinburgh, Scotland. She is a member of the Royal College of Physicians, U.K., and is registered with the General Medical Council, U.K. She currently serves as a member of the board of directors of AMAG Pharma, a company traded on NASDAQ.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs